Costall B, Naylor R J, Nohria V
Eur J Pharmacol. 1978 Jul 1;50(1):39-50. doi: 10.1016/0014-2999(78)90251-0.
Apomorphine and the putative dopamine agonist, 2-(N, N-dipropyl)-amino-5, 6-dihydroxytetralin induced dose-dependent climbing behaviour in the mouse which was measured in wire mesh lined cages as the percentage of time spent climbing in the 30 min period following the first climb and as the maximum time spent in a single climb throughout the drug effect. These These two measures were generally found to parallel excepting when the interacting agent caused muscular hypotonia. All potential interacting agents were given as pretreatments to determine changes in motor function which may interfere with the climbing induced by 1.0 mg/kg s.c. apomorphine. The possibility of a change in the apomorphine response to a sterotyped biting, which would also interfere with climbing, was also considered. Excluding these non-specific changes, climbing behaviour was shown to be antagonised, dose-dependently, by low doses of typical and atypical neuroleptic agents (haloperidol, fluphenazine, loxapine, pimozide, oxiperomide, clozapin, thioridazine, sulpiride, tiapride and metoclopramide) but not specifically by other psychoactive agents. Climbing behaviour was modified by serotonergic agents; the agonist quipazine reduced or abolished, whilst the antagonists, methysergide and cyproheptadine, enhanced the response. Picrotoxin specifically reduced climbing behaviour but sodium valproate exerted non-specific effects, precluding conclusions as to a GABA involvement. Cholinergic and noradrenergic involvements with climbing were also apparently eliminated by the ineffectiveness of atropine, aceperone, piperoxan and propranolol. The involvement of serotonin with climbing was extended to the actions of the neuroleptics: the antagonistic effects of typical neuroleptics (haloperidol, fluphenazine, loxapine) were markedly enhanced by combination with methysergide or cyproheptadine whilst the effects of clozapine, sulpiride and thioridazine were significantly reduced. The actions of metoclopramide, oxiperomide, pimozide and tiapride were not generally modified by such combinations. These differences are discussed in terms of differential abilities to induce extrapyramidal disturbances and the mouse climbing model is forwarded as a test with potential to detect antipsychotic agents of different activity spectra.
阿扑吗啡和假定的多巴胺激动剂2-(N,N-二丙基)-氨基-5,6-二羟基四氢萘可诱导小鼠产生剂量依赖性的攀爬行为。该行为在金属丝网衬里的笼子中进行测量,以首次攀爬后30分钟内攀爬所花费的时间百分比以及在整个药物作用期间单次攀爬所花费的最长时间来表示。一般发现这两种测量方法相互平行,但当相互作用的药物导致肌肉张力减退时除外。所有潜在的相互作用药物均作为预处理给药,以确定可能干扰1.0mg/kg皮下注射阿扑吗啡诱导的攀爬行为的运动功能变化。还考虑了阿扑吗啡反应改变为刻板咬啮行为(这也会干扰攀爬)的可能性。排除这些非特异性变化后,低剂量的典型和非典型抗精神病药物(氟哌啶醇、氟奋乃静、洛沙平、匹莫齐特、奥昔哌隆、氯氮平、硫利达嗪、舒必利、替阿普瑞和甲氧氯普胺)可剂量依赖性地拮抗攀爬行为,但其他精神活性药物则无特异性拮抗作用。5-羟色胺能药物可改变攀爬行为;激动剂喹哌嗪可减少或消除攀爬行为,而拮抗剂麦角新碱和赛庚啶则增强该反应。印防己毒素可特异性降低攀爬行为,但丙戊酸钠产生非特异性作用,无法得出关于γ-氨基丁酸参与的结论。阿托品、阿塞哌隆、哌罗克生和普萘洛尔无效,这也明显排除了胆碱能和去甲肾上腺素能与攀爬行为的关联。5-羟色胺与攀爬行为的关联扩展到了抗精神病药物的作用:典型抗精神病药物(氟哌啶醇、氟奋乃静、洛沙平)与麦角新碱或赛庚啶联合使用时,其拮抗作用明显增强,而氯氮平、舒必利和硫利达嗪的作用则显著减弱。甲氧氯普胺、奥昔哌隆、匹莫齐特和替阿普瑞的作用一般不受此类联合用药的影响。根据诱导锥体外系障碍的不同能力对这些差异进行了讨论,并提出将小鼠攀爬模型作为一种有可能检测不同活性谱抗精神病药物的试验。